Get the Stockscreener App
11.74
4.36%
0.49
After Hours:
11.68
-0.06
-0.51%
Rapt Therapeutics Inc stock is traded at $11.74, with a volume of 181.54K.
It is up +4.36% in the last 24 hours and up +10.65% over the past month.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
See More
Previous Close:
$11.25
Open:
$11.38
24h Volume:
181.54K
Relative Volume:
1.52
Market Cap:
$194.15M
Revenue:
$3.25M
Net Income/Loss:
$-116.80M
P/E Ratio:
-3.8492
EPS:
-3.05
Net Cash Flow:
$-98.17M
1W Performance:
+19.67%
1M Performance:
+10.65%
6M Performance:
+22.29%
1Y Performance:
-35.07%
1-Day Range:
$11.00
$11.84
1-Week Range:
$8.75
$11.84
52-Week Range:
$5.6652
$26.56
Rapt Therapeutics Inc Stock (RAPT) Company Profile
Name
Rapt Therapeutics Inc
Sector
Industry
Phone
(650) 489-9000
Address
561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA
Compare RAPT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RAPT
Rapt Therapeutics Inc
|
11.74 | 186.05M | 3.25M | -116.80M | -98.17M | -3.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Rapt Therapeutics Inc Stock (RAPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Upgrade | JP Morgan | Underweight → Neutral |
| May-22-25 | Resumed | H.C. Wainwright | Buy |
| Dec-26-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-13-24 | Downgrade | Stifel | Buy → Hold |
| Nov-11-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-11-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-14-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-10-24 | Downgrade | Barclays | Overweight → Equal Weight |
| May-10-24 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-22-24 | Downgrade | UBS | Buy → Neutral |
| Feb-21-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Feb-21-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-21-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-20-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-16-24 | Initiated | Evercore ISI | Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Sep-14-23 | Initiated | Berenberg | Buy |
| Aug-09-23 | Initiated | Stifel | Buy |
| Jun-15-23 | Initiated | Barclays | Overweight |
| Jan-04-23 | Initiated | Guggenheim | Buy |
| Dec-01-22 | Initiated | Goldman | Buy |
| Sep-21-22 | Initiated | CapitalOne | Overweight |
| May-24-22 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-09-21 | Initiated | JP Morgan | Overweight |
| Aug-12-21 | Initiated | SVB Leerink | Outperform |
| Jun-21-21 | Initiated | Piper Sandler | Overweight |
| Jun-01-20 | Initiated | H.C. Wainwright | Buy |
| May-19-20 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-13-20 | Initiated | ROTH Capital | Buy |
| Nov-25-19 | Initiated | BMO Capital Markets | Outperform |
| Nov-25-19 | Initiated | UBS | Buy |
| Nov-25-19 | Initiated | Wells Fargo | Outperform |
View All
Rapt Therapeutics Inc Stock (RAPT) Latest News
Will RAPT Therapeutics Inc. outperform tech stocksJuly 2025 Trends & Daily Risk Controlled Trade Plans - thegnnews.com
RAPT Therapeutics Inc. Recovery Likely Here’s What Data ShowsMarket Sentiment Review & Daily Price Action Insights - beatles.ru
How to forecast RAPT Therapeutics Inc. trends using time seriesWeekly Profit Analysis & Growth Focused Investment Plans - Newser
Understanding RAPT Therapeutics Inc.’s price movement2025 Price Action Summary & Free Real-Time Volume Trigger Notifications - Newser
RAPT Therapeutics Inc. stock daily chart insightsMarket Volume Report & Low Drawdown Momentum Trade Ideas - Newser
Has RAPT Therapeutics Inc. formed a bullish divergenceTrade Ideas & Safe Capital Preservation Plans - Newser
RAPT Therapeutics Inc. Builds Base for Possible Rebound2025 Analyst Calls & Fast Entry High Yield Tips - beatles.ru
What high frequency data says about RAPT Therapeutics Inc.2025 Price Momentum & Weekly Hot Stock Watchlists - Newser
Building trade automation scripts for RAPT Therapeutics Inc.2025 Market Overview & Smart Investment Allocation Insights - Newser
Sentiment analysis tools applied to RAPT Therapeutics Inc.Free Profit Target Stock Opportunity Monitor - Newser
Why RAPT Therapeutics Inc. stock attracts strong analyst attentionLow Cost High Gain Picks - newsyoung.net
RAPT Therapeutics: UBS maintains Neutral, raises PT to $9 from $8. - AInvest
Rapt Therapeutics (RAPT)'s Technical Outlook is Bright After Key Golden Cross - Yahoo Finance
Will RAPT Therapeutics Inc. continue its uptrendSector Rotation and Stock Opportunity Analysis - Newser
Volume spikes in RAPT Therapeutics Inc. stock – what they meanFree Smart Trade Plans With Risk Protection - Newser
Analyzing drawdowns of RAPT Therapeutics Inc. with statistical toolsAlgorithmic Forecast for Swing Trading Picks - Newser
Rapt Therapeutics (NASDAQ:RAPT) Cut to Sell at Wall Street Zen - Defense World
Historical volatility pattern of RAPT Therapeutics Inc. visualizedRisk Aware Trading Ideas with Alert Levels - Newser
HC Wainwright Issues Positive Forecast for RAPT Earnings - Defense World
Ranking RAPT Therapeutics Inc. among high performing stocks via toolsSmart Swing Picks with Confirmed Signals - Newser
Multi asset correlation models including RAPT Therapeutics Inc.Technical Insight Guide for Safer Trades - Newser
Applying Elliott Wave Theory to RAPT Therapeutics Inc.Buy and Hold Position Summary Review - Newser
Published on: 2025-08-09 04:24:12 - beatles.ru
Using AI based signals to follow RAPT Therapeutics Inc.Stock Entry Point Planner with Volume Spike - Newser
Using Ichimoku Cloud for RAPT Therapeutics Inc. technicalsAlpha Stock Picks with Chart Confirmation - Newser
RAPT Therapeutics Reports Q2 2025 Financial Results: Net Loss of $34.8 Million, Cash and Securities Valued at $169 Million. - AInvest
Full technical analysis of RAPT Therapeutics Inc. stockAlpha Trade Flow With Risk Calibration - Newser
Rapt Therapeutics’ Reverse Stock Split: Potential Pitfalls and Market Challenges - TipRanks
Wells Fargo lowers Rapt Therapeutics stock price target to $38 on model changes - Investing.com Canada
Wells Fargo Maintains RAPT Therapeutics(RAPT.US) With Buy Rating, Cuts Target Price to $38 - 富途牛牛
RAPT Therapeutics Reports Q2 2025 Financial Results - TipRanks
RAPT Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
RAPT Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Rapt Therapeutics reports Q2 EPS (65c), consensus (65c) - TipRanks
RAPT Therapeutics, Inc. SEC 10-Q Report - TradingView
RAPT Therapeutics Q2 net loss narrows to $17.6 mln, R&D expenses drop - MarketScreener
Rapt Therapeutics Inc Stock (RAPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.41%
0.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):